Search

Daniel B Tuse

from Sacramento, CA
Age ~73
Get Report
Also known as:
Daniel Barbara Tuse, Daniel T Tuse
Phone and address:
2695 13Th St, Sacramento, CA 95818
(916) 447-6013
Related to:
Pavel Mishin, 68Andrew Horne, 72Nadezhda Mishin, 66David Wykoff
Connected to:
Erika A Tusen, 42Holly Tush, 40Benjamin C Tusha, 50Brendan J Tusha, 37Sanyu Tushabe, 50Dave Tushar, 98Jamal Tushar, 31Samir Tushar, 36Jama B Tushaus, 49Michael F Tushaus, 72

Daniel Tuse Phones & Addresses

  • 2695 13Th St, Sacramento, CA 95818 (916) 447-6013
  • Fremont, CA
  • 7955 Spencer Ln, Vacaville, CA 95688
  • 104 Elm St, Menlo Park, CA 94025 (650) 566-0335
  • 1007 Henderson Ave, Menlo Park, CA 94025
  • Palo Alto, CA
  • Alameda, CA

Resumes

Resumes

Daniel Tuse Photo 1

Managing Director At Dt/Consulting Group

View page
Position:
Managing Director at DT/Consulting Group
Location:
San Francisco Bay Area
Industry:
Biotechnology
Work:
DT/Consulting Group
Managing Director
Daniel Tuse Photo 2

Managing Director At Dtconsulting Group

View page
Position:
Managing Director at DTConsulting Group
Location:
San Francisco Bay Area
Industry:
Biotechnology
Work:
DTConsulting Group
Managing Director
Education:
University of California, Davis

Business Records

Name / Title
Company / Classification
Phones & Addresses
Daniel Tuse
Principal
Dt Consulting
Business Consulting Services
7955 Spencer Ln, Vacaville, CA 95688
Daniel Tuse
Vice-president
VAXX, INC
Business Services at Non-Commercial Site
6393 N Desert Wind Cir, Tucson, AZ 85750
7955 Spence Ln Ind Cir, Vacaville, CA 95688
Daniel Tuse
Marketing Director
LARGE SCALE BIOLOGY CORPORATION
Coml Physical Research Mfg Medicinal/Botanicals Mgmt Consulting Svcs Mfg Pharmaceutical Preps · Medicinal and Botanical Manufacturing
3333 Vaca Vly Pkwy STE 1000, Vacaville, CA 95688
(707) 446-5502, (707) 446-5501, (707) 446-3917, (707) 469-2316
Daniel Tuse
Intrucept Biomedicine LLC
Pharmaceutical Research & Development
PO Box 5663, Vacaville, CA 95696
7955 Spencer Ln, Vacaville, CA 95688

Publications

Us Patents

Method For Inhibiting Inflammatory Disease

View page
US Patent:
6433012, Aug 13, 2002
Filed:
Sep 6, 2000
Appl. No.:
09/656144
Inventors:
Daniel Tuse - Menlo Park CA
Charles Hiebert - Sunnyvale CA
Keith R. Laderoute - Palo Alto CA
Nahid Waleh - Palo Alto CA
Assignee:
Large Scale Biology Corp. - Vacaville CA
SRI International - Menlo Park CA
International Classification:
A61K 3112
US Classification:
514532, 514535, 514543, 428450
Abstract:
The present invention relates to methods for effectively inhibiting inflammatory diseases, such as Crohns disease and ulcerative colitis. In other aspects, this invention relates to methods of reducing or inhibiting granulomas.

Episomal Non-Transforming Nucleic Acid Elements In Functional Genomic And Antigenic Applications

View page
US Patent:
20020182626, Dec 5, 2002
Filed:
Mar 15, 2002
Appl. No.:
10/098606
Inventors:
Daniel Tuse - Vacaville CA, US
International Classification:
C12Q001/68
G01N033/53
C12N015/87
US Classification:
435/006000, 435/007100, 435/455000
Abstract:
The present invention provides a method for functional genomic analysis and antigen prototyping by introducing episomal non-transforming non-viral vector-based cDNA or genomic libraries of donor organisms, pathogens, or cancer cells into host cells. The DNA libraries can be compacted without substantial aggregation to facilitate uptake by host cells. Antigen prototyping can be to identify antigens of pathogens that confer immuno-protection against the pathogens and antigens of cancer cells that confer immuno-protection against the cancer cells..

Self Antigen Vaccines For Treating B Cell Lymphomas And Other Cancers

View page
US Patent:
20030035807, Feb 20, 2003
Filed:
Feb 8, 2002
Appl. No.:
10/067790
Inventors:
Alison McCormick - Vacaville CA, US
Daniel Tuse - Menlo Park CA, US
Stephen Reinl - Sacramento CA, US
John Lindbo - Vacaville CA, US
Thomas Turpen - Vacaville CA, US
International Classification:
A61K039/395
C07K016/30
A01H005/00
US Classification:
424/185100, 800/288000, 530/388100, 424/155100
Abstract:
A polypeptide self-antigen useful in a tumor-specific vaccine mimics one or more epitopes of an antigen uniquely expressed by cells of the tumor. The polypeptide is preferably produced in a plant that has been transformed or transfected with nucleic acid encoding the polypeptide and is obtainable from the plant in correctly folded, preferably soluble form without a need for denaturation and renaturation. This plant-produced polypeptide is immunogenic without a need for exogenous adjuvants or other immunostimulatory materials. The polypeptide is preferably an scFv molecule that bears the idiotype of the surface immunoglobulin of a non-Hodgkin's (or B cell) lymphoma. Upon administration to a subject with lymphoma, the plant-produced, tumor-unique scFv polypeptide induces an idiotype-specific antibody or cell-mediated immune response against the lymphoma.

Self Antigen Vaccines For Treating B Cell Lymphomas And Other Cancers

View page
US Patent:
20030039659, Feb 27, 2003
Filed:
Feb 8, 2002
Appl. No.:
10/067892
Inventors:
Alison McCormick - Vacaville CA, US
Daniel Tuse - Menlo Park CA, US
Stephen Reinl - Sacramento CA, US
John Lindbo - Vacaville CA, US
Thomas Turpen - Vacaville CA, US
International Classification:
A61K039/00
C07K014/435
A01H001/00
US Classification:
424/185100, 800/288000, 530/350000
Abstract:
A polypeptide self-antigen useful in a tumor-specific vaccine mimics one or more epitopes of an antigen uniquely expressed by cells of the tumor. The polypeptide is preferably produced in a plant that has been transformed or transfected with nucleic acid encoding the polypeptide and is obtainable from the plant in correctly folded, preferably soluble form without a need for denaturation and renaturation. This plant-produced polypeptide is immunogenic without a need for exogenous adjuvants or other immunostimulatory materials. The polypeptide is preferably an scFv molecule that bears the idiotype of the surface immunoglobulin of a non-Hodgkin's (or B cell) lymphoma. Upon administration to a subject with lymphoma, the plant-produced, tumor-unique scFv polypeptide induces an idiotype-specific antibody or cell-mediated immune response against the lymphoma.

Self Antigen Vaccines For Treating B Cell Lymphomas And Other Cancers

View page
US Patent:
20030044417, Mar 6, 2003
Filed:
Mar 31, 2000
Appl. No.:
09/539382
Inventors:
Alison McCormick - Vacaville CA, US
Daniel Tuse - Menlo Park CA, US
Stephen Reinl - Sacramento CA, US
John Lindbo - Vacaville CA, US
Thomas Turpen - Menlo Park CA, US
International Classification:
C12P021/06
C12P021/04
A61K039/395
A61K039/40
A61K039/42
A61K039/00
A61K039/38
US Classification:
424/184100, 424/277100, 424/192100, 424/131100, 424/132100, 424/133100, 435/069100, 435/070100, 435/070210
Abstract:
A polypeptide self-antigen useful in a tumor-specific vaccine mimics one or more epitopes of an antigen uniquely expressed by cells of the tumor. The polypeptide is preferably produced in a plant that has been transformed or transfected with nucleic acid encoding the polypeptide and is obtainable from the plant in correctly folded, preferably soluble form without a need for denaturation and renaturation. This plant-produced polypeptide is immunogenic without a need for exogenous adjuvants or other immunostimulatory materials. The polypeptide is preferably an scFv molecule that bears the idiotype of the surface immunoglobulin of a non-Hodgkin's (or B cell) lymphoma. Upon administration to a subject with lymphoma, the plant-produced, tumor-unique scFv polypeptide induces an idiotype-specific antibody or cell-mediated immune response against the lymphoma.

Self Antigen Vaccines For Treating B Cell Lymphomas And Other Cancers

View page
US Patent:
20030044420, Mar 6, 2003
Filed:
Feb 8, 2002
Appl. No.:
10/067893
Inventors:
Alison McCormick - Vacaville CA, US
Daniel Tuse - Menlo Park CA, US
Stephen Reinl - Sacramento CA, US
John Lindbo - Vacaville CA, US
Thomas Turpen - Vacaville CA, US
International Classification:
A61K039/00
C07H021/04
C12P021/02
C12N005/06
C07K014/435
C07K016/28
US Classification:
424/185100, 530/350000, 530/388800, 435/069300, 435/325000, 435/320100, 536/023530
Abstract:
A polypeptide self-antigen useful in a tumor-specific vaccine mimics one or more epitopes of an antigen uniquely expressed by cells of the tumor. The polypeptide is preferably produced in a plant that has been transformed or transfected with nucleic acid encoding the polypeptide and is obtainable from the plant in correctly folded, preferably soluble form without a need for denaturation and renaturation. This plant-produced polypeptide is immunogenic without a need for exogenous adjuvants or other immunostimulatory materials. The polypeptide is preferably an scFv molecule that bears the idiotype of the surface immunoglobulin of a non-Hodgkin's (or B cell) lymphoma. Upon administration to a subject with lymphoma, the plant-produced, tumor-unique scFv polypeptide induces an idiotype-specific antibody or cell-mediated immune response against the lymphoma.

Endothelial Cell Derived Hematopoietic Growth Factor

View page
US Patent:
20030124091, Jul 3, 2003
Filed:
Oct 25, 2002
Appl. No.:
10/281423
Inventors:
Daniel Tuse - Vacaville CA, US
Thomas Davis - Oak Hill VA, US
Alison McCormick - Vacaville CA, US
Sharon Wannberg - Germantown MD, US
Assignee:
Large Scale Biology Corporation
International Classification:
A61K038/20
A61K038/19
A61K038/18
A61K039/00
US Classification:
424/085100, 424/085200, 424/185100, 514/012000
Abstract:
The present invention relates to human and porcine endothelial cell derived growth factors (EDHF) that contain one or a mixture of more than one endothelial cell proteins having a molecular weight greater than about 30 kDa. The EDHF is added to culture medium to expand tri-lineage pre-dendritic myleomonocytic progenitor cells and culture endothelial cells. The present invention also relates to a method of amplifying myeloid dendritic cell precursors both in vitro and in vivo. The EDHF is also used therapeutically to increase myeloid dendritic cell production in vivo to enhance the activity of vaccines.

Self Antigen Vaccines For Treating B-Cell Lymphomas And Other Cancers

View page
US Patent:
20060018900, Jan 26, 2006
Filed:
Aug 22, 2005
Appl. No.:
11/209592
Inventors:
Alison McCormick - Vacaville CA, US
Daniel Tuse - Vacaville CA, US
Stephen Reinl - Sacramento CA, US
John Lindbo - Wooster OH, US
Thomas Turpen - Vacaville CA, US
International Classification:
A61K 39/395
A61K 48/00
C40B 40/08
US Classification:
424133100, 514044000
Abstract:
A polypeptide self-antigen useful in a tumor-specific vaccine mimics one or more epitopes of an antigen uniquely expressed by cells of the tumor. The polypeptide is preferably produced in a plant that has been transformed or transfected with nucleic acid encoding the polypeptide and is obtainable from the plant in correctly folded, preferably soluble form without a need for denaturation and renaturation. This plant-produced polypeptide is immunogenic without a need for exogenous adjuvants or other immunostimulatory materials. The polypeptide is preferably an scFv molecule that bears the idiotype of the surface immunoglobulin of a non-Hodgkin's (or B cell) lymphoma. Upon administration to a subject with lymphoma, the plant-produced, tumor-unique scFv polypeptide induces an idiotype-specific antibody or cell-mediated immune response against the lymphoma.
Control profile
Daniel B Tuse from Sacramento, CA, age ~73 Get Report